Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes

Similar documents
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical

Psychopharmacological treatment of first episode psychosis

Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.

Class Update: Oral Antipsychotics

First Episode Schizophrenia

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

Care of the Acutely Agitated Patient. Objectives. Agitation Defined

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan

EARLY ONSET SCHIZOPHRENIA

Are Two Antipsychotics Better Than One?

PORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016

Optima Health. Schizophrenia. Next Review Date 9/19

Working with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers

The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan

Treatment of Schizophrenia

Is there a case for earlier use of antipsychotic LAIs in schizophrenia? John Donoghue Liverpool

RUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics

February 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by

Psychosis and Agitation in Dementia

Individualising antipsychotic treatment for patients with schizophrenia John Donoghue Liverpool

Overview. Optimizing Treatment in Schizophrenia: An Update. Illness Phases. First Episode

LAI Antipsychotics Frequently Asked Questions

Psychiatric Emergencies and ER Violence

Scottish Medicines Consortium

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Minimising the Impact of Medication on Physical Health in Schizophrenia

Improving Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

I received help from Bosch Health Care

The British Approach to Understanding and Treating Psychosis

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia

Your footnote

Eight Core Principles for Treating Psychosis in Adolescents. Sanjiv Kumra MD. Off-Label Use. Psychosis/Schizophrenia in U.S. Children/Adolescents

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Class Update with New Drug Evaluations: Antipsychotics

Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Update on First Psychotic Episodes in Childhood and Adolescence. Cheryl Corcoran, MD Assistant Professor of Psychiatry Columbia University

Abbreviated Class Review: Long-Acting Injectable Antipsychotics

Clinical Guideline for the Management of Bipolar Disorder in Adults

November 2014 MRC2.CORP.X.00004

Method. NeuRA First versus second generation antipsychotics August 2016

Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review

Bipolar Disorder in Youth

Activity Overview. Target Audience

Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD

Resubmission. Scottish Medicines Consortium

Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications

POT WEED CHRONIC GREEN KUSH BUD HERB

Platforms for Performance: Clinical Dashboards to Improve Quality and Safety 2011 Midyear Clinical Meeting

National Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia

CDEC FINAL RECOMMENDATION

CLINICAL EFFECTIVENESS

schizophrenia with An early stage of distinct treatment needs MANAGING FIRST-EPISODE PSYCHOSIS

Treatment of Children and Adolescents with Schizophrenia

Role of Clozapine in Treatment-Resistant Schizophrenia

Clinician's Guide to Prescribing Depot Antipsychotics

Behavior Management in Children with Cancer

Mr. E, age 37, has a 20-year history

Schizophrenia and bipolar disorders are lifelong

The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder

Antipsychotics in Bipolar

CLINICAL EFFECTIVENESS

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics

Optimizing Care for Patients With Schizophrenia

Partnering with Consumers to Address First Episode Psychosis

Is Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?

Schizophrenia: A Lifelong Illness

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia

Robert Heinssen, PhD, ABPP North Carolina Practice Improvement Collaborative North Carolina State University, Raleigh NC November 7, 2014

Supplementary Online Content

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Treatment of Bipolar disorder

Is Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?

Pharmacotherapy of psychosis and schizophrenia in youth

( delirium ) 15%- ( extrapyramidal syndrome ) risperidone olanzapine ( extrapyramidal side effect ) olanzapine ( Delirium Rating Scale, DRS )

Pharmacological Treatment of Aggression in the Elderly

Managing First Episode Psychosis

New Medications in Early Psychosis

Current Non-Preferred Agents

Is everything that makes sense true?

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Pharmacological Managment of Treatment Resistant Schizophrenia. Jean-Marie Batail - France 21 st July 2015

Acute Treatment of Schizophrenia Multiple-treatments meta-analysis

Fidelity and Outcomes in Community Care

Metaanalytische Evaluierung atypischer Antipsychotika

SCHIZOPHRENIA SPECTRUM DISORDERS Psychiatry 2 Practical # 2

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009

Shriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in Alzheimer s Disease and Other Dementias

Managing acute psychotic disorders in an emergency department

Management of the Agitated and Violent ED Patient. Lauren Klein, MD, MS Faculty Physician Hennepin County Medical Center Minneapolis, Minnesota

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses

Transcription:

Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes

Learning Objectives Initiate low-dose antipsychotic medication that minimizes physical health hazards Preemptively assess for and mitigate new side effects during treatment Incorporate psychosocial interventions to help patients set and achieve life goals

Pretest Question 1 For an acutely psychotic patient at risk of imminent danger to self or others, but who is naïve to antipsychotic medication, the best choice would be: 1. IM benzodiazepine such as lorazepam 2. IM olanzapine with lorazepam 3. IM haloperidol with lorazepam 4. IM olanzapine without lorazepam 5. Seclusion and restraints without medication

Case Presentation: First-Onset Psychosis A 22-year-old man is brought to the ER by his parents. They report that the man has been yelling at the television when the news comes on, muttering to himself frequently, and insisting on closing all of the blinds in the house during the day and night. In the waiting room, the man paces back and forth, clenching and unclenching his fists and mumbling to himself. He appears unkempt and has a slight odor. He now begins pacing faster and shouting a few words from time to time.

TREATING FIRST-EPISODE PSYCHOSIS

Rapid Emergency Treatments for Acutely Psychotic Patients Reduce stressful environmental factors De-escalation techniques for cooperative patients Short-acting parenteral antipsychotic With or without parenteral benzodiazepine Greater risk of respiratory depression With or without parenteral anticholinergic Can cause oversedation; limit to use in setting of EPS Rapidly dissolving oral formulations or oral concentrates Ideally, choose antipsychotics or benzodiazepines with short half-lives and use at the lowest effective doses Reserve seclusion and mechanical restraints as last resorts Stahl SM et al. CNS Spectrums 2013;18(3):150-62.

Parenteral Options for Acutely Psychotic Patients Onset Initial Dose Considerations Antipsychotics Aripiprazole 60 m 9.75 mg IM Haloperidol 1 2 m IV 30 60 m IM 5 mg IM/IV IV haloperidol carries increased risk of QTc prolongation; slow IV drip may be used with appropriate cardiac monitoring Olanzapine 15 45 m 10 mg IM Use with a BZ increases risk of cardiopulmonary depression Ziprasidone 30 45 m 20 mg IM Benzodiazepines Diazepam 30 m 5 10 IV Avoid IM because of unpredictable absorption Lorazepam Midazolam 2 5 m IV 15 30 m IM 120 IV 4 6 h IM 1 2 mg IM/IV 2.5 5 mg IM/IV Most frequently used; also available as intranasal Higher risk of respiratory depression compared to diazepam or lorazepam Dean N et al. Emerg Med Clin North Am 2015;33(4):739-52.

After Acute Stabilization: Therapeutic Alliance and Low-Dose Antipsychotic Educate patient Establish relationship with family Careful documentation of symptoms (may change over time) Low-dose antipsychotic No evidence favoring any antipsychotic or antipsychotic class over another May need to use adjunct benzodiazepine (short half-life) to relieve distress, insomnia, and behavioral disturbances while antipsychotic medication takes effect Stahl SM et al. CNS Spectrums 2013;18(3):150-62; Freudenreich. Clin Schizophr Related Psychoses 2012;6(3):115-21.

Additional Considerations Affective psychopathology Adverse effects: first-episode patients have higher rates of: EPS when treated at chronic antipsychotic doses Possibly metabolic complications Monitor weight, lipid profile, fasting blood sugar Hason A et al. World J Biol Psychiatry 2012;13(5):318-78.

REDUCING RELAPSE AND READMISSION

Factors Affecting Outcomes Duration of untreated psychosis >6 months No remission within 3 months Persistent substance/cannabis use Schizophrenia diagnosis vs. brief psychotic episode Poor/deteriorating premorbid social functioning Early age of onset Development of EPS Distressing emotional environment Stahl SM et al. CNS Spectrums 2013;18(3):150-62; Robinson D et al. Arch Gen Psychiatry 1999;56:241-7; Friis S et al. Psychiatr Services 2016;67:438-43.

Duration of Untreated Psychosis Penttila M et al. Br J Psychiatry 2014;205:88-94.

No Remission Within 3 Months: Consider Clozapine? Applied treatment algorithm: 2 sequential SGA trials followed by clozapine Findings reinforce high proportion of response initially in FEP But <20% response to second SGA in those with a poor response to the first Olanzapine was superior to risperidone Response rate increased for those who agreed to a trial of clozapine % 100 90 80 70 60 50 40 30 20 10 0 Response: CGI of 1 or 2 and/or BPRS thought disorder subscale score 6 TRIAL 1 n=244 olanzapine or risperidone TRIAL 2 n=60 olanzapine or risperidone Agid O et al. J Clin Psychiatry 2011;72(11):1439-44. TRIAL 3 n=28 clozapine

Continued vs. Discontinued Cannabis Use in Patients With Psychosis Greater risk of psychosis relapse in nonuser Greater risk of psychosis relapse in continued cannabis user Schoeler T et al. Lancet Psychiatry 2016;3(3):215-25.

Rates of Relapse With Continued vs. Discontinued Treatment 178 asymptomatic patients treated for 1 year with AP. Randomized to quetiapine 400 mg/day (n=89) or placebo (n=89). Quet: 41% (95% CI 29 53). PBO: 79% (95% CI 68 90) (p<0.001). Chen EYH et al. BMJ 2010;310:c4024.

Most First-Episode Patients Will Accept an LAI 46 first-episode patients with 16 weeks of lifetime antipsychotic exposure randomly assigned to continuation of oral vs. LAI (1:2 ratio) Those randomized to LAI were given option of opting out to continue oral Primary outcome: adherence at week 12 Results 73% of those randomized to LAI (19/26) chose to stay on LAI Patients accepting LAI were significantly more likely to be adherent at the week 12 endpoint (p=0.035) Weiden PJ et al. J Clin Psychiatry 2009;70(10):1397-406.

Treatment Beyond the Positive Symptoms: Psychosocial Strategies Patients want jobs and independent living Combined supported employment/education program Assertive community treatment (ACT) Social skills training Cognitive behavior therapy (CBT) Weight management Cognitive remediation Peer support and peer-delivered services Combined psychosocial interventions Family intervention Muller H et al. Eur Arch Psychiatry Clin Neurosci 2014;264(suppl 1):S17-25; Yesufu-Udechuku A et al. Br J Psychiatry 2015;206:268-74.

Coordinated Specialty Care (CSC) Team-based Assertive case management Individual or group psychotherapy Supported employment and education services Family education and support Low-dose antipsychotic

RAISE Early Treatment Program: NAVIGATE vs. Community Care NAVIGATE participants: Were more likely to endorse receipt of key services Remained in treatment longer Primary Outcome: QLS Total Score Effect size: 0.31 Kane JM et al. Am J Psychiatry 2016;173:362-72.

Summary Early identification and treatment can limit functional loss in schizophrenia Antipsychotic treatment should be dosed low First-episode patients are more sensitive to side effects Onset of psychosis completely upends the lives of individuals who are transitioning into adulthood; psychosocial strategies and support are ESSENTIAL